Zobrazeno 1 - 10
of 33
pro vyhledávání: '"J E, Krook"'
Autor:
S V, Rajkumar, J M, Reid, P J, Novotny, S L, Safgren, B W, Scheithauer, P S, Johnson, S, Nair, R F, Morton, A K, Hatfield, J E, Krook, M M, Ames, J C, Buckner
Publikováno v:
Journal of neuro-oncology. 49(3)
We conducted a randomized phase II study to determine the efficacy of dacarbazine (DTIC) in recurrent gliomas. Patients were randomly assigned to receive either DTIC 750 mg/m2 IV day 1 every 28 days (Arm A) or DTIC 200 mg/m2 IV days 1-5 every 28 days
Autor:
H C, Pitot, J A, Knost, M R, Mahoney, J, Kugler, J E, Krook, A K, Hatfield, D J, Sargent, R M, Goldberg
Publikováno v:
Cancer. 89(8)
Topoisomerase I inhibitors have demonstrated clinical activity in patients with metastatic colorectal carcinoma. The authors performed a Phase II study to evaluate the objective tumor response rate of 2 different doses and schedules of 9-aminocamptot
Autor:
J A, Bonner, J A, Sloan, K M, Rowland, G G, Klee, J W, Kugler, J A, Mailliard, M, Wiesenfeld, J E, Krook, A W, Maksymiuk, E G, Shaw, R S, Marks, E A, Perez
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(2)
The level of serum neuron-specific enolase (NSE) has been implicated as a prognostic factor for patients with small cell lung cancer (SCLC). A prospective evaluation was undertaken to assess the prognostic significance of pretreatment NSE and treatme
Autor:
E A, Perez, D W, Hillman, P J, Stella, J E, Krook, L C, Hartmann, T R, Fitch, A K, Hatfield, J A, Mailliard, S, Nair, C G, Kardinal, J N, Ingle
Publikováno v:
Cancer. 88(1)
This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m(2) by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic b
Autor:
J N, Ingle, V J, Suman, P A, Johnson, J E, Krook, J A, Mailliard, R H, Wheeler, C L, Loprinzi, E A, Perez, V C, Jordan, M, Dowsett
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(7)
The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of letrozole on tamoxifen (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus letrozole
Autor:
J N, Ingle, V J, Suman, C G, Kardinal, J E, Krook, J A, Mailliard, M H, Veeder, C L, Loprinzi, R J, Dalton, L C, Hartmann, C A, Conover, M N, Pollak
Publikováno v:
Cancer. 85(6)
Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lin
Autor:
T E, Elliott, R P, Dinapoli, J R, O'Fallon, J E, Krook, J D, Earle, R F, Morton, R, Levitt, L K, Tschetter, B W, Scheithauer, D M, Pfeifle, D I, Twito, R A, Nelimark
Publikováno v:
Journal of neuro-oncology. 33(3)
We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and DBD with RT and BCNU in patients with high-grade astrocytoma.A total of 238 patients with supratentorial grade 3 and grade 4 astrocytoma were
Autor:
S R, Alberts, J N, Ingle, P R, Roche, S S, Cha, L E, Wold, G H, Farr, J E, Krook, H S, Wieand
Publikováno v:
Cancer. 78(4)
The measurement of estrogen receptors (ER) in breast cancer specimens has traditionally been assessed with a dextran-coated charcoal assay (DCCA). More recently the immunohistochemical staining (IHC) method has gained increasing popularity because of
Autor:
R M, Goldberg, C G, Moertel, H S, Wieand, J E, Krook, A J, Schutt, M H, Veeder, J A, Mailliard, R J, Dalton
Publikováno v:
Cancer. 76(6)
The purpose of this study was to determine by randomized, controlled, double-blind evaluation whether therapy with the somatostatin analogue, octreotide, would delay tumor progression and improve survival of patients with metastatic colorectal carcin
Autor:
J N, Ingle, S A, Kuross, J A, Mailliard, C L, Loprinzi, S H, Jung, R A, Nelimark, J E, Krook, H J, Long
Publikováno v:
Cancer. 74(6)
Doxorubicin generally is considered to be the most effective single chemotherapeutic agent for the treatment of breast cancer. The major cumulative dose-limiting toxicity is cardiac toxicity, which may be related to the formation of free radicals wit